Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

Noam Barda; Michal Canetti; Mayan Gilboa; Victoria Indenboim; Keren Asraf; Yael Weiss-Ottolenghi; Sharon Amit; Daniel Zibly; Ram Doolman; Ella Mendelson; Dror Harats; Laurence S. Freedman; Yitshak Kreiss; Yaniv Lustig; Gili Regev-Yochay

doi:10.2807/1560-7917.ES.2022.27.39.2200701

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

Noam Barda, Michal Canetti, Mayan Gilboa, Victoria Indenboim, Keren Asraf, Yael Weiss-Ottolenghi, Sharon Amit, Daniel Zibly, Ram Doolman, Ella Mendelson, Dror Harats, Laurence S. Freedman, Yitshak Kreiss, Yaniv Lustig, Gili Regev-Yochay

Ben-Gurion University of the Negev, Tel Aviv University

Research output: Contribution to journal › Article › peer-review

Abstract

We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98- 1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.

Original language	American English
Article number	2200701
Journal	Eurosurveillance
Volume	27
Issue number	39
DOIs	https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200701
State	Published - 1 Sep 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Epidemiology
Public Health, Environmental and Occupational Health
Virology

Access to Document

10.2807/1560-7917.ES.2022.27.39.2200701

Cite this

Barda, N., Canetti, M., Gilboa, M., Indenboim, V., Asraf, K., Weiss-Ottolenghi, Y., Amit, S., Zibly, D., Doolman, R., Mendelson, E., Harats, D., Freedman, L. S., Kreiss, Y., Lustig, Y., & Regev-Yochay, G. (2022). Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022. Eurosurveillance, 27(39), Article 2200701. https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200701

@article{178dd291ab434a6ea9d2b345fecf67c6,

title = "Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022",

abstract = "We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95\% CI: 1.27-1.97) in Spikevax and 1.16-fold (95\% CI: 0.98- 1.37) in Comirnaty vaccinees. Nearly 60\% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95\% CI: 0.62-1.09) and Comirnaty (0.86; 95\% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95\% CI: 0.13-0.62) and 0.51 (95\% CI: 0.27-0.96), respectively.",

author = "Noam Barda and Michal Canetti and Mayan Gilboa and Victoria Indenboim and Keren Asraf and Yael Weiss-Ottolenghi and Sharon Amit and Daniel Zibly and Ram Doolman and Ella Mendelson and Dror Harats and Freedman, \{Laurence S.\} and Yitshak Kreiss and Yaniv Lustig and Gili Regev-Yochay",

year = "2022",

month = sep,

day = "1",

doi = "10.2807/1560-7917.ES.2022.27.39.2200701",

language = "American English",

volume = "27",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control (ECDC)",

number = "39",

}

Barda, N, Canetti, M, Gilboa, M, Indenboim, V, Asraf, K, Weiss-Ottolenghi, Y, Amit, S, Zibly, D, Doolman, R, Mendelson, E, Harats, D, Freedman, LS, Kreiss, Y, Lustig, Y & Regev-Yochay, G 2022, 'Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022', Eurosurveillance, vol. 27, no. 39, 2200701. https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200701

TY - JOUR

T1 - Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

AU - Barda, Noam

AU - Canetti, Michal

AU - Gilboa, Mayan

AU - Indenboim, Victoria

AU - Asraf, Keren

AU - Weiss-Ottolenghi, Yael

AU - Amit, Sharon

AU - Zibly, Daniel

AU - Doolman, Ram

AU - Mendelson, Ella

AU - Harats, Dror

AU - Freedman, Laurence S.

AU - Kreiss, Yitshak

AU - Lustig, Yaniv

AU - Regev-Yochay, Gili

PY - 2022/9/1

Y1 - 2022/9/1

N2 - We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98- 1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.

AB - We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98- 1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.

UR - http://www.scopus.com/inward/record.url?scp=85138961736&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES.2022.27.39.2200701

DO - 10.2807/1560-7917.ES.2022.27.39.2200701

M3 - Article

C2 - 36177870

SN - 1025-496X

VL - 27

JO - Eurosurveillance

JF - Eurosurveillance

IS - 39

M1 - 2200701

ER -

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this